反応式
Cl[CH:2]1[C:7](=[O:8])[CH2:6][C:5]([CH2:14][CH2:15][C:16]2[CH:21]=[CH:20][C:19]([O:22][CH3:23])=[C:18]([Cl:24])[CH:17]=2)([CH:9]2[CH2:13][CH2:12][CH2:11][CH2:10]2)[O:4][C:3]1=[O:25].[SH:26][C:27]1[N:40]=[C:30]2[N:31]=[CH:32][C:33]([C:35]([O:37][CH2:38][CH3:39])=[O:36])=[CH:34][N:29]2[N:28]=1>O>[Cl:24][C:18]1[CH:17]=[C:16]([CH2:15][CH2:14][C:5]2([CH:9]3[CH2:13][CH2:12][CH2:11][CH2:10]3)[O:4][C:3](=[O:25])[C:2]([S:26][C:27]3[N:40]=[C:30]4[N:31]=[CH:32][C:33]([C:35]([O:37][CH2:38][CH3:39])=[O:36])=[CH:34][N:29]4[N:28]=3)=[C:7]([OH:8])[CH2:6]2)[CH:21]=[CH:20][C:19]=1[O:22][CH3:23]参加物
反応物 2
生成物 1
試薬・触媒・溶媒 1
実験手順
The title compound was prepared as described in Example C(70), where 3-chloro-6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione was used in place of 3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione and ethyl 2-mercapto[1,2,4]triazolo-[1,5-a]pyrimidine-6-carboxylate was used in place of 6-hydroxy-8-mercaptopurine monohydrate. 1H NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H2O (3.35 ppm) peak areas) δ 1.34 (t, J=7.1 Hz, 3H) 1.55-1.74 (m, 8H) 2.07 (m, 1H) 2.22 (m, 2H) 2.63 (d, J=8.2 Hz, 2H) 2.75 (d, J=17.6 Hz, 2H) 3.00 (d, J=15.0 Hz, 1H) 3.81 (s 3H) 4.38 (m, 2H) 7.06 (t, J=8.8 Hz, 1H) 7.25 (s, 1H) 7.27 (s, 1H) 7.30 (m, 1H) 9.13 (s, 1H) 9.26 (s, 1H). MS (APCI) calcd for C27H29ClN4O6S: 573.07; found M=573.1.
出典と根拠
- ORDレコード
- ord-bc864ec66db242a4afce565107022ac8
- 出典データセット
- uspto-grants-2009_01
- 特許番号
- US07473790B2
関連ノート
読み込み中…